Revelation Biosciences, Inc. (REVBW) company profile

Revelation is a clinical-stage biopharmaceutical company that develops therapeutic candidates to treat and prevent inflammatory conditions, focusing primarily on kidney disorders. The company's therapeutic pipeline is built upon its proprietary formulation platform known as Gemini, which utilizes a synthetic Toll-like receptor 4 agonist to rebalance dysregulated immune responses and reduce excess cellular inflammation. Its principal clinical-stage development programs include GEM-AKI for the treatment of acute kidney injury and GEM-CKD for the management of chronic kidney disease. Because its products remain in clinical and preclinical development, Revelation does not currently market commercial drugs, though its intended patient base consists of individuals suffering from severe acute or progressive renal illnesses.

Revelation operates without internal manufacturing facilities and relies on third-party contract manufacturers and specialized suppliers to produce active pharmaceutical ingredients for its drug candidates. The company is headquartered in San Diego, California, where it conducts its core operational and corporate activities.

Summary of the business section of Revelation Biosciences's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of February 23, 2026, we had 8 full-time employees and one part-time employee, 5 of whom are engaged in research and development activities or operations and 4 of whom are engaged in general and administrative activities or operations.”